Thomas Rubio

1.1k total citations
38 papers, 725 citations indexed

About

Thomas Rubio is a scholar working on Epidemiology, Pulmonary and Respiratory Medicine and Infectious Diseases. According to data from OpenAlex, Thomas Rubio has authored 38 papers receiving a total of 725 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Epidemiology, 13 papers in Pulmonary and Respiratory Medicine and 10 papers in Infectious Diseases. Recurrent topics in Thomas Rubio's work include Antibiotics Pharmacokinetics and Efficacy (10 papers), Cystic Fibrosis Research Advances (8 papers) and Pharmaceutical studies and practices (5 papers). Thomas Rubio is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (10 papers), Cystic Fibrosis Research Advances (8 papers) and Pharmaceutical studies and practices (5 papers). Thomas Rubio collaborates with scholars based in United States, Spain and Switzerland. Thomas Rubio's co-authors include Arnold L. Smith, Dieter Adam, Bettina C. Hilman, Ron Dagan, Deborah Church, Richard B. Moss, Y. Aujard, Heikki Peltola, Robert J. Kuhn and Roger Echols and has published in prestigious journals such as Clinical Infectious Diseases, The American Journal of Medicine and The Journal of Infectious Diseases.

In The Last Decade

Thomas Rubio

36 papers receiving 680 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas Rubio United States 14 286 256 207 146 120 38 725
P. E. Gower United Kingdom 18 388 1.4× 114 0.4× 127 0.6× 80 0.5× 29 0.2× 38 979
H. F. L. Guiot Netherlands 19 380 1.3× 174 0.7× 116 0.6× 120 0.8× 93 0.8× 32 1.1k
G W Amsden United States 7 297 1.0× 136 0.5× 144 0.7× 71 0.5× 64 0.5× 7 661
R Vejlşgaard Denmark 17 379 1.3× 75 0.3× 82 0.4× 50 0.3× 54 0.5× 63 765
Kathryn A. Newman United States 14 194 0.7× 106 0.4× 152 0.7× 103 0.7× 50 0.4× 25 918
Tetsuro Muratani Japan 19 401 1.4× 70 0.3× 134 0.6× 370 2.5× 104 0.9× 56 1.0k
M Kitzis France 20 344 1.2× 127 0.5× 406 2.0× 480 3.3× 46 0.4× 67 1.0k
J. C. Gould United Kingdom 18 301 1.1× 149 0.6× 68 0.3× 47 0.3× 60 0.5× 57 924
D. Merzbach Israel 16 262 0.9× 114 0.4× 39 0.2× 46 0.3× 87 0.7× 70 843
J. Kosmidis Greece 17 294 1.0× 37 0.1× 296 1.4× 206 1.4× 34 0.3× 47 794

Countries citing papers authored by Thomas Rubio

Since Specialization
Citations

This map shows the geographic impact of Thomas Rubio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Rubio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Rubio more than expected).

Fields of papers citing papers by Thomas Rubio

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Rubio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Rubio. The network helps show where Thomas Rubio may publish in the future.

Co-authorship network of co-authors of Thomas Rubio

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Rubio. A scholar is included among the top collaborators of Thomas Rubio based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Rubio. Thomas Rubio is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rubio, Thomas, et al.. (2021). Trends in Pediatric Candidemia: Epidemiology, Anti-Fungal Susceptibility, and Patient Characteristics in a Children’s Hospital. Journal of Fungi. 7(2). 78–78. 13 indexed citations
2.
Piqueras, Ana Isabel, et al.. (2020). Recent changes in candidemia trends in a tertiary hospital (2011–2018). Revista Iberoamericana de Micología. 37(3-4). 87–93. 5 indexed citations
3.
Montero, José, et al.. (2018). Hellp syndrome complicated by subcapsular liver hematoma. a surgical emergency. HPB. 20. S481–S482. 1 indexed citations
4.
Rubio, Thomas, et al.. (2016). Gonococcal Infections in Infants and Children. Clinical Pediatrics. 1 indexed citations
5.
Irisarri, F., María Gutiérrez Urtiaga, J. Solà, et al.. (2004). Progresos en el control de la infección por el VIH y el sida en Navarra, 1985-2003. Anales del Sistema Sanitario de Navarra. 27(2). 221–31. 8 indexed citations
6.
Rubio, Thomas, et al.. (2001). Abdominal actinomycosis with hydronephrosis in childhood. The Pediatric Infectious Disease Journal. 20(9). 901–903. 4 indexed citations
7.
Rubio, Thomas, Michael V. Miles, John Lettieri, et al.. (1997). Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation. The Pediatric Infectious Disease Journal. 16(1). 112–117. 36 indexed citations
8.
Church, Deborah, Robert J. Kuhn, Thomas Rubio, et al.. (1997). Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Pediatric Infectious Disease Journal. 16(1). 97–105. 63 indexed citations
9.
Weisman, Leonard E., Barbara J. Stoll, Thomas Rubio, et al.. (1992). Intravenous immune globulin therapy for early-onset sepsis in premature neonates. The Journal of Pediatrics. 121(3). 434–443. 56 indexed citations
10.
Moss, Richard B., et al.. (1991). Evaluation of the Immunologic Cross-Reactivity of Aztreonam in Patients with Cystic Fibrosis Who Are Allergic to Penicillin and/or Cephalosporin Antibiotics. Clinical Infectious Diseases. 13(Supplement_7). S598–S607. 25 indexed citations
11.
Rubio, Thomas. (1990). Ciprofloxacin in the treatment of Pseudomonas infection in children with cystic fibrosis. Diagnostic Microbiology and Infectious Disease. 13(2). 153–155. 23 indexed citations
12.
Jungbluth, Gail L., Frederick H. Wirth, Thomas Rubio, David M. Janicke, & William J. Jusko. (1988). Developmental Pharmacokinetics of Mezlocillin in 4 NewbornInfants. Developmental Pharmacology and Therapeutics. 11(6). 317–321. 4 indexed citations
13.
Adelman, Raymond D., Frederick H. Wirth, & Thomas Rubio. (1987). A controlled study of the nephrotoxicity of mezlocillin and gentamicin plus ampicillin in the neonate. The Journal of Pediatrics. 111(6). 888–893. 17 indexed citations
14.
Rohn, Reuben D., et al.. (1984). Familial third-fourth pharyngeal pouch syndrome with apparent autosomal dominant transmission. The Journal of Pediatrics. 105(1). 47–51. 39 indexed citations
15.
Lietman, Paul S., et al.. (1984). Developmental pharmacokinetics of mezlocillin in newborn infants. The Journal of Pediatrics. 104(5). 773–781. 8 indexed citations
16.
Armstrong, Carl W., et al.. (1984). Outbreak of Fatal Arsenic Poisoning Caused by Contaminated Drinking Water. Archives of Environmental Health An International Journal. 39(4). 276–279. 53 indexed citations
17.
Rubio, Thomas, et al.. (1982). Pharmacokinetic studies of mezlocillin in newborn infants. Journal of Antimicrobial Chemotherapy. 9(suppl A). 241–244. 7 indexed citations
18.
Johnson, David H., et al.. (1981). Bacterial endocarditis with flail mitral valve leaflet. The Journal of Pediatrics. 98(3). 426–429. 5 indexed citations
19.
Rohn, Reuben D. & Thomas Rubio. (1980). Neck pain due to acute suppurative thyroiditis and thyroglossal duct abscess. Journal of Adolescent Health Care. 1(2). 155–158. 7 indexed citations
20.
Rubio, Thomas & Harris D. Riley. (1973). Serious Systemic Infection Associated with the Use of Indwelling Intravenous Catheters. Southern Medical Journal. 66(6). 633–637. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by P. E. Gower Breakdown of academic impact, for papers by H. F. L. Guiot Breakdown of academic impact, for papers by G W Amsden Breakdown of academic impact, for papers by R Vejlşgaard Breakdown of academic impact, for papers by Kathryn A. Newman Breakdown of academic impact, for papers by Tetsuro Muratani Breakdown of academic impact, for papers by M Kitzis Breakdown of academic impact, for papers by J. C. Gould Breakdown of academic impact, for papers by D. Merzbach Breakdown of academic impact, for papers by J. Kosmidis
Rankless by CCL
2026